Bacteriophages and Their Immunological Applications against Infectious Threats

Table 1

Bacteriophage and phage-derived proteins tested in clinical trials.

Drug	Condition	Phase	Results	Identifier
WPP-201 bacteriophage	Venous leg ulcers	I	This study found no safety concerns with; the bacteriophage treatment [57]	NCT00663091
T4 phage cocktail	Diarrhea	I/II	Oral phages showed a safe gut transit in; children but failed to achieve intestinal amplification; and to improve diarrhea outcome, possibly due to; insufficient phage coverage and too low E. coli; pathogen titres requiring higher oral phage doses [58]	NCT00937274
E. coli phage cocktail	Wound infection	I/II; ongoing	No results published yet	NCT02116010
Topical anti-Staphylococcus; bacteriophage therapy	Diabetic foot; staphylococcal infections	I/II; ongoing	No results published yet	NCT02664740
Lysin CF-301	S. aureus bloodstream infections	I; ongoing	No results published yet	NCT02439359
VAPGH P128	Nasal S. aureus; colonization; S. aureus-infected; venous ulcer	I/II; completed	No results published yet	NCT01746654